Siemens Healthineers Announces Collaboration Agreement for Assay Development with an Initial Focus on Multiple Sclerosis

Siemens HealthineersSiemens Healthineers announced today a master collaboration agreement with Novartis Pharma AG to design, develop, and commercialize diagnostic tests for therapeutic products across Novartis' therapeutic pipeline. The initial program supports the development of a serum neurofilament light chain (sNFL) immunoassay to support Novartis’ MS and other neuroscience programs.

NFL is a highly specific biomarker for nerve cell injury measured in cerebral spinal fluid and blood . Blood NFL levels have been reported to change in variety of serious neurological conditions including MS and have been related to disease activity and disability outcomes.(1)

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by myelin destruction and axonal damage in the brain, optic nerves and spinal cord.(2) The Multiple Sclerosis foundation estimates that more than 2.5 million people in the world and more than 400,000 people in the United States have MS. By 2025, an estimated $23 billion will be spent annually on treating the disease.(3)

Novartis, as a leading pharmaceutical company in neuroscience, has a strong ongoing commitment to bring transformative treatments to people suffering from neurological conditions, such as Multiple Sclerosis, where there is a high unmet need.

This collaboration will leverage Siemens Healthineers’ expertise in the development of innovative clinical diagnostic solutions that may be run on Siemens Healthineers global population of ADVIA Centaur and Atellica immunoassay platforms designed for use in hospitals, reference laboratories, and specialty laboratories.

"We are looking forward to our collaboration with Novartis as it promises to yield innovative diagnostic solutions to address critical unmet clinical needs," said Deepak Nath, PhD, President, Laboratory Diagnostics, Siemens Healthineers. "Our initial focus on blood-based diagnostic solutions for Multiple Sclerosis patients is another example of Siemens Healthineers commitment to shape the future of precision medicine."

The global burden of chronic neurology disease4 continues to increase, and a 2016 study concluded that neurology disorders are the second leading cause of death and leading cause of DALYs (disability-adjusted life-year). sNFL expands Siemens Healthineers Laboratory Diagnostics Neurology test menu, which also includes AB42 and Tau for the clinical diagnosis of Alzheimer’s disease. Both AB42 and Tau were recently granted FDA Breakthrough Device Designation for expedited reviews.

Additionally, Siemens Health laboratory, based in Berkeley, California offers a range of neurobiomarker testing services including sNFL, for biopharmaceutical company therapy development programs. Siemens Healthineers offers a comprehensive range of Neuroradiology products and services, and was the first company worldwide to announce a comprehensive amyloid imaging solution for the U.S. market for the detection of amyloid plaques.

About Siemens Healthineers

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers ability to provide high-quality, efficient care to patients. In fiscal 2019, which ended on September 30, 2019, Siemens Healthineers, which has approximately 52,000 employees worldwide, generated revenue of €14.5 billion and adjusted profit of €2.5 billion.

1. Khalil et al.: Neurofilaments as biomarkers in neurological disorders. Nature Reviews; Neurology. 2018; 14: 577–589.
2. Guthrie E. Multiple sclerosis: a primer and update. Adv Studies Pharm. 2007;4(11):313-317.
3. iHealthcareAnalyst. "Global Multiple Sclerosis Drugs Market $23.5 Billion by 2025." Published January 14, 2020.
4. "Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016." Lancet Neurol. 2019 May; 18(5): 459–480.

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...